Skip to main content

Table 1 Baseline demographic and primary indication for fully enrolled patients

From: BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study

Patient CharacteristicsPatients
N = 77
Age at Enrollment (years ± SD)62.1 ± 15.4
Gender
 Male41 (53.2%)
 Female36 (46.8%)
Height (in ± SD)67.8 ± 4.8
Weight (lbs ± SD)205.6 ± 7.9
BMI (kg/m2 ± SD)31.4 ± 6.6
Race
 White71 (92.2%)
 Black or African American5 (6.5%)
 Not Specified1 (1.3%)
Primary Indication for Insertion
 Management for known AT/AF37 (48.1%)
 Diagnosis of unexplained syncope17 (22.1%)
 Palpitations8 (10.4%)
 Diagnosis of suspected AT/AF6 (7.79%)
 Cryptogenic Stroke4 (5.19%)
 Near syncope3 (3.90%)
 Other cardiac arrhythmia2 (2.60%)
Other Medical History
 AF41 (53.2%)
 Atrial Flutter14 (18.2%)
 Bradycardia19 (24.7%)
 Cardiomyopathy10 (13.0%)
 Hypertension48 (62.3%)
 Hypotension3 (3.9%)
 Syncope20 (26.0%)
 Ventricular Tachycardia5 (6.5%)
 Other AT10 (13.0%)
History of Ablation31 (40.3%)
 Ablation for AF21 (27.3%)
 Ablation for Atrial Flutter6 (7.79%)
 Ablation for Other AT3 (3.90%)
 Ablation for Ventricular Tachycardia1 (1.3%)
  1. Values are presented as n (%) unless otherwise indicated. AF atrial fibrillation, AT atrial tachycardia